BAJAJ BROKING

Notification close image
No new Notification messages
card image
Cash UR Drive Marketing IPO is Open!
Apply for the Cash UR Drive Marketing IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Piramal Pharma Q1 Results FY25-26: Revenue Declines Marginally by 1%, Net Loss Narrows to ₹82 Crores

Piramal Pharma Q1 Results FY25-26: Revenue Declines Marginally by 1%, Net Loss Narrows to ₹82 Crores

Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635) reported its consolidated financial results for the quarter ended 30th June 2025 (Q1FY26). The company reported a marginal decline of 1% in revenue from operations, reaching ₹1,934 crores compared to ₹1,951 crores in Q1 FY25. Notably, net loss after tax reduced to ₹82 crores from ₹89 crores in the same quarter last year, reflecting an 8% year-on-year improvement.

Quick Insights

  • Revenue from Operations: ₹1,934 crores in Q1FY26, down 1% YoY

  • EBITDA: ₹165 crores, a 26% decline from ₹224 crores in Q1FY25

  • EBITDA Margin: Declined to 9% from 11%

  • PAT (after exceptional item): ₹(82) crores, an 8% improvement YoY

  • As of 29th July, 2025, 2:30 PM, Piramal Pharma share price was ₹206.07.

  • Net-Debt to EBITDA Ratio: 2.6x

  • USFDA Inspection: Aurora facility (Canada) closed with zero observations

  • Sustainability: ESG rating of ‘61’ for FY2024 by NSE Sustainability Ratings and Analytics Limited

PIRAMAL PHARMA LIMITED

Trade

190.65-6.38 (-3.23 %)

Updated - 01 August 2025
198.00day high
DAY HIGH
190.00day low
DAY LOW
5047984
VOLUME (BSE)

Quarterly - Piramal Pharma Q1 Results FY25-26

The company’s overall revenue experienced a slight decline due to the impact of destocking in one large CDMO (Contract Development and Manufacturing Organisation) product. Excluding this, underlying revenue saw early double-digit growth. Other income increased sharply to ₹58 crores (up 199% YoY), boosting total income to ₹1,992 crores.

Consolidated Financials Overview

Particulars

Q1FY26 (₹ Cr)

Q1FY25 (₹ Cr)

YoY Change

Revenue from Operations

1,934

1,951

(1)%

Other Income

58

20

199%

Total Income

1,992

1,971

1%

EBITDA

165

224

(26)%

Finance Cost

86

107

(19)%

Depreciation

197

185

7%

Exceptional Item

21

-

NA

Profit Before Tax

(79)

(45)

(75)%

Net Profit After Tax

(82)

(89)

8%

Segment Highlights

Contract Development and Manufacturing Organisation (CDMO)

  • Revenue declined to ₹997 crores from ₹1,057 crores (down 6% YoY).

  • Base business (excluding destocking) saw mid-teen growth.

  • Overseas facilities drove growth with improved profitability.

  • Nutrition Supplements and Generic API also contributed positively.

  • Successfully completed USFDA inspection at Aurora (Canada) with zero observations.

  • Initiated expansion at the Lexington (US) facility for sterile injectable drug products.

Complex Hospital Generics (CHG)

  • Revenue rose marginally to ₹637 crores from ₹631 crores (up 1% YoY).

  • Inhalation Anaesthesia: Sluggish due to timing of institutional orders; recovery expected in H2FY26.

  • Received USFDA approval for Digwal facility (India) for Sevoflurane API and finished products.

  • Intrathecal Therapy and Injectable Anaesthesia faced temporary shipment and supply issues.

  • Launched Neoatricon® in select EU markets; more launches anticipated in Q2FY26.

Piramal Consumer Healthcare (PCH)

  • Strong revenue growth of 15% YoY to ₹302 crores (from ₹263 crores).

  • Power Brands grew 18% YoY, contributing 49% of PCH sales.

  • E-commerce sales increased 41% YoY, now forming 23% of PCH revenue.

  • 7 new products launched in Q1FY26.

  • Advertising and promotional spending accounted for 13% of PCH sales.

Sector Expectations for Piramal Pharma Q1 Results FY25-26

Piramal Pharma’s flat revenue and subdued EBITDA performance generally aligned with sector expectations for a mixed quarter. The sector continues to grapple with supply chain pressures, inflationary input costs, and regulatory scrutiny. However, the consumer healthcare division’s robust double-digit growth, as well as strategic capacity expansions in CDMO and CHG, position the company well compared to broader industry trends.

Biotech funding constraints and delayed decision-making by customers impacted early-stage development projects across the industry, a trend also reflected in Piramal Pharma’s CDMO division. Institutional order timing further influenced sector-wide hospital generic sales, also seen in Piramal’s CHG segment performance.

Management Commentary

Nandini Piramal, Chairperson of Piramal Pharma Limited, stated, “Excluding the impact of destocking in one large on-patent commercial product, our CDMO business delivered mid-teen revenue growth during the quarter, accompanied by improvement in EBITDA margin, especially at our overseas sites. Growth in our CHG business is also expected to pick up for the remaining part of the year given the timing of some of the institutional orders. Our consumer business delivered healthy growth, in line with our expectations, driven by power brands and ecommerce sales. Withstanding the near-term challenges, we believe we are on track to achieve our FY2030 aspirations of becoming a US$2bn revenue company with 25% EBITDA margin and high-teen ROCE.”

Source: Q1 FY25-26 Quarterly Results uploaded on 28th July on BSE.

For a complete overview of all upcoming and past earnings reports, check the Quarterly Results Calendar 2025.

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4.2 App Rating

icon-with-text

4 Languages

icon-with-text

₹5600+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|